* A corporate client of Hybridan LLP.
** Potential means Intention to Float (ITF) or similar announcement has been made.
***Arranged by type of listing and date of announcement.
****Alphabetically arranged and priced on Share Price and Market Capitalisation during the time of writing on the day of Publication.
Admissions:
None
Delistings:
None
What’s baking in the oven?
It's a little empty
London Stock Exchange: Main Market and AIM
ActiveOps 237.5p £187.5m (AOM.L)
The provider of Decision Intelligence software for service operations released its audited results for the year ended 31 March 2026. The Group delivered double digit revenue growth, a record number of new customer wins and continued strong cash generation in the year. ARR was up 46% to £41.5m, with total revenue up 48% to £45m. Adjusted EBITDA was £4.3m, while loss before tax was £2m, after £3m in exceptional costs went to the acquisition of Enlighten Group. Cash remains strong at £23.8m. Trading in the first few months of FY27 has been in line with the Board's expectations, including sales of CaseWorkiQ to a new US banking customer, and expansions within several existing customers.
Braemar 239.0p £79.03m (BMS.L)
The provider of chartering, investment and risk management advice to the shipping and energy markets updated ahead of its AGM to be held today. Positive momentum in the new financial year continued, building on the strong second half of the year ended 28 February 2026. The Board remains confident in the Company's ability to deliver profitable growth for the year in line with market expectations. The Company consensus for the year ended 28 February 2027 is for revenue of £139.7m and underlying operating profit (before acquisition-related expenditure) of £14.2m. The Company has also appointed Grant Foley, the current CFO and COO, with immediate effect.
Cropper (James) 380.0p £33.44m (CRPR.L)
The Advanced Materials and Paper & Packaging group announced the completion of a refinancing of its debt facilities. As part of the refinancing, the Group will make a part-repayment of £7.1m on its existing UK bank loan, funded from the Group's cash resources and the new invoice discounting facility, with the remaining balance repayable in reduced quarterly instalments through to March 2030. In addition, the maturity of the Group's US bank loan has been extended by 12 months, with the final repayment of $3.2m deferred to December 2027, improving liquidity headroom during this period. Alongside the debt refinancing, the Group has agreed to make a one-off contribution into its defined benefit pension schemes of £0.6m, with the previously agreed contribution schedule reduced by £0.35m in aggregate across the period to September 2027. In addition, the Group has agreed to bring forward the next triennial actuarial valuation of the pension schemes by 12 months to March 2027.
Eco Animal Health Group 95.50p £62.68m (EAH.L)
The global animal health Company marketing and developing branded veterinary products to improve livestock productivity and welfare announces the commercial launch of ECOVAXXIN MS, its poultry vaccine against Mycoplasma synoviae across the EU with its official launch event in Madrid, Spain. ECOVAXXIN MS represents the first product from ECO's proprietary R&D pipeline to reach commercial market entry. The vaccine provides active immunisation of future layer and breeder chickens from four weeks of age to reduce air-sac and foot-pad lesions and egg production losses caused by M. synoviae infections. The infection causes significant economic loss, particularly in laying hens, where egg production in affected layers can be reduced by 5-10%.
Georgina Energy 5.50p £12.17m (GEX.L)
The helium, hydrogen and natural resources development and production Company based in Australia confirmed that contractors and personnel continue onsite undertaking the pre-drill site works required for the Q3 Hussar drilling program. Current operations are proceeding as planned to enable the testing of this exciting prospect, with 300 km² of areal closure and as one of the largest subsalt Helium, Hydrogen and Hydrocarbons prospects in onshore Australia. The Contracted Ensign Rig 970 remains scheduled for mobilisation to site following completion of the current preparatory works, with an anticipated spud date in September 2026. Hussar will target primary subsalt reservoir formations, including the Townsend Formation and fractured Neoproterozoic basement lithologies, for helium, hydrogen and natural gas.
Hamak Strategy Limited 0.70p £2.83m (HAMA.L)
The Company combining advanced gold exploration in West Africa with a disciplined Digital Asset Treasury Management strategy announced that it has entered into an amendment and restatement of its existing funding arrangements with YA II PN Ltd, an institutional investor managed by Yorkville Advisors Global, LP. The amended package restates the outstanding balance of the previous £2.5m convertible loan note announced on 4 December 2025 into a non-convertible loan of £1,657,671.23. The Board believes the revised structure materially improves funding visibility, removes the conversion rights attached to the previous CLN and provides a clearer repayment pathway while allowing the Company to retain working capital flexibility for its operational and strategic objectives.
Insig AI 12.25p £15.69m (INSG.L)
The provider of AI-led analytics and machine-learning solutions has signed a Memorandum of Understanding with the principals of a company to be incorporated in the Far East that is launching a new macro fund. The Fund Engine will be integral to the fund's operations and decision making. The initial engagement is expected to be for 15 months with expected revenues of $240k, with $120k
expected within three months of the commencing of the contract. Insig AI will design, build, and host the Fund Engine for the customer which will bring information sources on which the fund will rely on into one repository, made available via a web application together with third-party large language models (LLM) for analysis and decision support. The domain specific knowledge in workflows and how they interact with LLMs is, the CEO claims, a core strength.
Trifast 70.8p £95.56m (TRI.L)
The international specialist in the design, engineering, manufacture, and distribution of high-quality engineered fastenings announced its audited results for the full year ended 31 March 2026. Revenue was down 7.3% to £207.1m (Constant Exchange Rate) as anticipated, reflecting softer market demand alongside the strategic decision to focus on the quality of revenue. The underlying EBIT increased to £16.3m (CER) (FY25: £14.9m), with EBIT margin improving to 7.8% (CER) (FY25: 6.7%) through continued margin management and operational efficiency actions. The Board remains confident in achieving the Group's medium-term EBIT margin target of >10%, underpinned by structural improvements in efficiency, mix and pricing.
Zephyr Energy 3.65p £71.84m (ZPHR.L)
The Company focused on the rocky mountains region announced a further increase in its operated land position in the Paradox Basin, Utah, U.S. through the successful acquisition of an additional 2,294 acres of Utah Trust Lands Administration leases. This new acquisition gives Zephyr an increased acreage footprint immediately to the north of its White Sands Unit. The acreage was nominated for auction by Zephyr and was acquired through a sealed-bid process. The related leases have a five-year primary term and a 16.67% lease royalty. The acquisition cost associated with the leases was paid from the Company's existing cash resources.
Aquis Market:
DXS International 1.35p £0.9m (AQSE:DXSP)*
The UK healthcare technology provider updated on trading for the financial year to 30 April 2026 ahead of the publication of its audited results for the year ended 30 April 2026. For the year under review, group turnover is expected to be marginally lower than the previous financial year, with annual revenues of approximately £3.4m. The reduction primarily reflects lower R&D tax credit income recognised in the period. Despite this modest reduction in revenue, the Board reported that the Company expects to deliver a small profit for the year, representing an improvement from the prior year's loss of approximately £90k. This reflects continued operational discipline and management focus on efficiency and cost control. The Group's balance sheet position has also strengthened during the year under review.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
